Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR6 | P51684 | 1/20 | 0.52 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | REN | P00797 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | FOLH1 | Q04609 | 6/20 | 0.35 |
| ▸ | SIRT5 | Q9NXA8 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL413898 | 0.93 | CCR6 (0.51) | CCR6PAX8HTTRENSMN1; SMN2 | |
| SCHEMBL416891 | 0.90 | CCR6 (0.48) | CCR6PAX8RENSMN1; SMN2 | |
| SCHEMBL418499 | 0.81 | CCR6 (0.50) | CCR6PAX8RENSMN1; SMN2 | |
| SCHEMBL13884597 | 0.78 | CCR6 (0.61) | CCR6PAX8HTTRENSMN1; SMN2 | |
| SCHEMBL413799 | 0.78 | CCR6 (0.50) | CCR6PAX8HTT | |
| SCHEMBL413897 | 0.76 | CCR6 (0.53) | CCR6PAX8HTT | |
| SCHEMBL461994 | 0.76 | CCR6 (0.55) | CCR6PAX8FOLH1SIRT5 | |
| SCHEMBL9699019 | 0.76 | HTT (0.63) | CCR6PAX8HTTSMN1; SMN2FOLH1 | |
| SCHEMBL413768 | 0.74 | CCR6 (0.64) | CCR6PAX8HTTSMN1; SMN2FOLH1 | |
| SCHEMBL7762084 | 0.73 | SMN1; SMN2 (0.40) | SMN1; SMN2FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8664409-B2 | Process for the preparation of (poly) aminoalkylaminoacetamide derivatives of epipodophyllotoxin useful for their applications in therapeutics as anticancer agent | PIERRE FABRE MEDICAMENT (FR) | 2014-03-04 | — | — | US | disclosed |
| US-20120022273-A1 | PROCESS FOR THE PREPARATION OF (POLY) AMINOALKYLAMINOACETAMIDE DERIVATIVES OF EPIPODOPHYLLOTOXIN USEFUL FOR THEIR APPLICATIONS IN THERAPEUTICS AS ANTICANCER AGENT | PIERRE FABRE MEDICAMENT (FR) | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022273-A1 | PROCESS FOR THE PREPARATION OF (POLY) AMINOALKYLAMINOACETAMIDE DERIVATIVES OF EPIPODOPHYLLOTOXIN USEFUL FOR THEIR APPLICATIONS IN THERAPEUTICS AS ANTICANCER AGENT | PTMA, NPEPPS, DNPEP | CCR6 3824/4885PAX8 2180/4885HTT 2168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.